[시장보고서]당뇨병성 신증 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2033년)

당뇨병성 신증 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2033년)

Diabetic Nephropathy Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

상품코드 : 1539340

리서치사 : Persistence Market Research

발행일 : 2024년 08월

페이지 정보 : 영문 213 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,995

￦ 7,224,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295

￦ 10,550,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495

￦ 12,286,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

Persistence Market Research는 최근 세계 당뇨병성 신증 시장에 대한 상세한 조사 보고서를 발표하여 시장 촉진요인, 동향, 기회 및 과제와 같은 시장 역학에 대한 자세한 인사이트를 제공했습니다. 이 보고서는 헬스케어 및 제약 부문의 이해관계자들에게 시장 구조와 향후 전망에 대한 종합적인 이해를 제공하는 것을 목표로 하고 있습니다.

주요 인사이트

세계 시장 매출(2022년) : 27억 달러
추정 시장 가치(2033년) : 49억 달러
세계 시장 성장률(2022-2033년 CAGR) : 6.8%

당뇨병성 신증 세계 시장 - 보고서 범위:

당뇨병성 신증 시장은 당뇨병의 심각한 합병증인 당뇨병성 신증(DKD)을 관리하기 위한 의약품 및 치료제의 개발, 생산 및 유통에 초점을 맞추고 있습니다. 이 시장을 주도하는 것은 전 세계 당뇨병 유병률의 증가와 그에 따른 당뇨병성 신증 유병률의 증가입니다. 이 시장에는 ACE 억제제, ARB, 당뇨병 환자의 신장 손상 진행을 늦추는 기타 약물 등 다양한 제품이 포함되어 있습니다.

시장 성장 촉진요인:

당뇨병 환자 증가

당뇨병성 신증은 당뇨병의 주요 합병증으로, 전 세계 당뇨병 유병률이 증가함에 따라 당뇨병성 신증의 발병률도 증가하고 있습니다. 당뇨병성 신증은 말기 신부전의 주요 원인이며, 당뇨병 환자는 비당뇨병 환자에 비해 이 질환이 발생할 확률이 10배 더 높습니다. 당뇨병 환자 수가 계속 증가함에 따라 당뇨병성 신증을 관리하기 위한 효과적인 치료 및 중재에 대한 수요도 증가하여 시장 성장을 주도하고 있습니다.

인식 제고와 조기 진단

당뇨병과 그 합병증으로 인한 위험에 대한 인식이 높아지면서 당뇨병성 신증의 조기 진단과 관리가 증가하고 있습니다. 의료 서비스 제공자들은 당뇨병 환자의 신장 질환에 대한 정기적인 검진에 초점을 맞추고 있으며, 이는 조기 개입과 환자 결과 개선으로 이어지고 있습니다. 이러한 적극적인 접근 방식은 당뇨병성 신증 시장의 성장을 더욱 촉진할 것으로 예상됩니다.

시장의 과제

높은 치료비

당뇨병성 신증의 높은 치료비용이 시장 성장의 큰 장벽으로 작용하고 있습니다. 당뇨병성 신증(DKD) 환자는 합병증이 없는 당뇨병 환자에 비해 의료비용이 훨씬 높으며, NCBI에 게재된 "Direct medical cost of nephropathy in patients with type 2 diabetes-International Urology and Nephrology'라는 제목의 연구에 따르면, DKD 환자의 추정 의료비는 603달러(283-1267달러)인 반면, 합병증이 없는 당뇨병 환자의 추정 의료비는 222달러(141-292달러)로 나타났습니다. 이러한 비용 격차는 특히 저렴한 의료 서비스에 대한 접근성이 제한적인 저소득 국가에서 경제적 부담을 초래할 수 있습니다.

제한된 치료 옵션과 전문 지식 부족

저소득 국가와 개발도상국에서는 당뇨병성 신증 치료에 대한 계획과 자원이 부족하고, 훈련된 전문의가 부족하여 큰 어려움을 겪고 있습니다. 또한, 당뇨병성 신증에 대한 완벽한 치료법은 현재 존재하지 않으며, 기존의 약물 요법은 질병을 관리하거나 진행을 지연시키는 데만 도움이 됩니다. 이러한 제약은 세계 당뇨병성 신증 시장의 주요 억제요인으로 작용하고 있습니다.

본 보고서에서 다루는 주요 질문들

세계 당뇨병성 신증 시장의 성장을 촉진하는 주요 요인은 무엇인가?
당뇨병성 신증 치료제의 채택을 주도하는 소비자층은 누구인가?
의학 연구와 치료법의 발전이 경쟁 상황에 어떤 영향을 미치고 있는가?
세계 당뇨병성 신증 시장의 주요 플레이어는 누구이며, 시장 지위를 유지하기 위해 어떤 전략을 채택하고 있는가?
세계 당뇨병성 신증 시장의 새로운 트렌드와 전망은?

소개/주요 조사 결과
시장 규모(금액) 분석, 2019-2023년
시장 규모(금액) 분석과 예측, 2024-2033년
- 이뇨제
- 안지오텐신 수용체 차단제
- 안지오텐신 전환효소 억제제(ACE 억제제)
- 나트륨-글루코스 수송 단백질 2(SGLT2) 억제제
- 기타
약물 종류별 시장 매력 분석

제9장 당뇨병별 : 세계 시장 분석

소개/주요 조사 결과
시장 규모(금액) 분석, 2019-2023년
시장 규모(금액) 분석과 예측, 2024-2033년
- 1형 당뇨병
- 2형 당뇨병
당뇨병별 시장 매력 분석

제10장 투여 경로별 : 세계 시장 분석

소개/주요 조사 결과
시장 규모(금액) 분석, 2019-2023년
시장 규모(금액) 분석과 예측, 2024-2033년
- 경구
- 비경구
- 기타
투여 경로별 시장 매력 분석

제11장 유통 채널별 : 세계 시장 분석

소개/주요 조사 결과
시장 규모(금액) 분석, 2019-2023년
시장 규모(금액) 분석과 예측, 2024-2033년
- 병원 약국
- 소매 약국
- 온라인 약국
- 기타
투여 경로별 시장 매력 분석

제12장 지역별 : 세계 시장 분석

소개
시장 규모(금액) 분석, 2019-2023년
시장 규모(금액) 분석과 예측, 2024-2033년
- 북미
- 라틴아메리카
- 유럽
- 동아시아
- 남아시아
- 오세아니아
- 중동 및 아프리카(MEA)
지역별 시장 매력 분석

제13장 북미 시장 분석

제14장 라틴아메리카 시장 분석

제15장 유럽 시장 분석

제16장 동아시아 시장 분석

제17장 남아시아 시장 분석

제18장 오세아니아 시장

제19장 중동 및 아프리카 시장 분석

제20장 시장 구조 분석

기업 계층별 시장 분석
주요 기업의 시장 점유율 분석
시장 입지 분석

제21장 경쟁 분석

경쟁 대시보드
경쟁 벤치마크
경쟁 상세
- AstraZeneca(UK.)
- Pfizer Inc(US.)
- Allergan, Inc(Ireland)
- Bristol-Myers Squibb Company(US.)
- Endo International plc(Ireland)
- Dr. Reddy's Laboratories Ltd(India)
- Sun Pharmaceutical Industries Ltd(India)
- Teva Pharmaceutical Industries Ltd(Israel)
- Novartis AG(Switzerland)
- Eli Lilly and Company(India)
- Mylan NV(US.)
- Cipla Inc(India)
- Lupin(India)
- Aurobindo Pharma(India)
- Sanofi(France)
- Fresenius SE &Co. KGaA(Germany)
- F. Hoffmann-La Roche Ltd(Switzerland)
- Takeda Pharmaceutical Company Limited(Japan)
- Abbott(US.)

제22장 사용되는 가정과 두문자어

제23장 조사 방법

ksm

영문 목차

영문목차

Persistence Market Research has recently published an in-depth report on the global diabetic nephropathy market, offering detailed insights into market dynamics, including drivers, trends, opportunities, and challenges. This report aims to provide a comprehensive understanding of the market structure and future outlook, catering to stakeholders involved in the healthcare and pharmaceutical sectors.

Key Insights:

Global Market Revenue (2022): US$ 2.7 Billion
Estimated Market Value (2033): US$ 4.9 Billion
Global Market Growth Rate (CAGR 2022-2033): 6.8%

Global Diabetic Nephropathy Market - Report Scope:

The diabetic nephropathy market is focused on the development, production, and distribution of medications and treatments aimed at managing diabetic kidney disease (DKD), a serious complication of diabetes mellitus. The market is driven by the increasing prevalence of diabetes worldwide, which in turn is escalating the incidence of diabetic nephropathy. This market encompasses a range of products, including ACE inhibitors, ARBs, and other medications that slow the progression of kidney damage in diabetic patients.

Market Growth Drivers:

Rising Prevalence of Diabetic Patients

Diabetic nephropathy is a major complication of diabetes mellitus, and with the rising global prevalence of diabetes, the incidence of diabetic nephropathy is also increasing. Diabetic nephropathy is a leading cause of end-stage renal failure, with patients having diabetes mellitus being 10 times more likely to develop this condition compared to those without diabetes. As the number of diabetic patients continues to rise, so does the demand for effective treatments and interventions to manage diabetic nephropathy, driving the market growth.

Increasing Awareness and Early Diagnosis

With growing awareness of the risks associated with diabetes and its complications, there has been an increase in early diagnosis and management of diabetic nephropathy. Healthcare providers are focusing on regular screening of diabetic patients for kidney damage, which has led to early intervention and improved patient outcomes. This proactive approach is expected to further fuel the growth of the diabetic nephropathy market.

Market Challenges:

High Cost of Treatment

The high cost of treating diabetic nephropathy is a significant barrier to market growth. Patients with diabetic kidney disease (DKD) incur substantially higher medical costs compared to those with diabetes but without complications. According to a study published in NCBI titled "Direct medical cost of nephropathy in patients with type 2 diabetes - International Urology and Nephrology," the estimated cost for a patient with DKD was $603 (283-1267) USD, compared to $222 (141-292) USD for a diabetic patient without complications. This cost disparity can result in financial strain, particularly in low-income countries where access to affordable healthcare is limited.

Limited Treatment Options and Lack of Expertise

In low-income and less developed countries, inadequate planning and resources for diabetic nephropathy therapy, coupled with a shortage of trained specialists, present significant challenges. Moreover, there is currently no complete cure for diabetic nephropathy; existing medications only help in managing or delaying the progression of the disease. These limitations are major restraints on the global diabetic nephropathy market.

Key Questions Answered in the Report:

What are the primary factors driving the growth of the global diabetic nephropathy market?
Which consumer segments are leading the adoption of diabetic nephropathy treatments?
How are advancements in medical research and treatment methods influencing the competitive landscape?
Who are the key players in the global diabetic nephropathy market, and what strategies are they employing to maintain their market position?
What are the emerging trends and future prospects in the global diabetic nephropathy market?

Competitive Intelligence and Business Strategy:

Leading players in the global diabetic nephropathy market, such as Abbott Laboratories, Bayer AG, and Novartis AG, are focusing on research and development, strategic collaborations, and expanding their product portfolios to maintain a competitive edge. These companies are investing in the development of novel therapies that can better manage the progression of diabetic nephropathy. Additionally, collaborations with healthcare providers and government agencies are enhancing market credibility and driving the adoption of new treatment protocols. Leveraging digital platforms to increase awareness and patient engagement is also a key strategy to strengthen market positioning.

Key Companies Profiled:

AstraZeneca (UK.)
Pfizer Inc (US.)
Allergan, Inc (Ireland)
Bristol-Myers Squibb Company (US.)
Endo International plc (Ireland)
Dr. Reddy's Laboratories Ltd (India)
Sun Pharmaceutical Industries Ltd (India)
Teva Pharmaceutical Industries Ltd (Israel)
Novartis AG (Switzerland)
Eli Lilly and Company (India)
Mylan NV (US.)
Cipla Inc (India)
Lupin (India)
Aurobindo Pharma (India)
Sanofi (France)
Fresenius SE & Co. KGaA (Germany)
F. Hoffmann-La Roche Ltd (Switzerland)
Takeda Pharmaceutical Company Limited (Japan)
Abbott (US.)

Key Segments Covered in Diabetic Nephropathy Industry Research

Drug Class:

Diuretics
Angiotensin Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
Others

Diabetes Type:

Type-1 Diabetes
Type-2 Diabetes

Route of Administration:

Oral
Parenteral
Others

Distribution Channel:

Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East and Africa

1. Executive Summary

1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends

4. Key Success Factors

4.1. Product Adoption Analysis
4.2. Disease Epidemiology
4.3. Regulatory Landscape
4.4. Pipeline Assessment
4.5. PESTEL Analysis
4.6. Porter's Analysis
4.7. Value Chain Analysis

5. Market Background

5.1. Macro-Economic Factors
- 5.1.1. Global GDP Growth Outlook
- 5.1.2. Global Healthcare Outlook
- 5.1.3. Global Renal Disease Market Outlook
5.2. Forecast Factors - Relevance & Impact
- 5.2.1. Development of Novel Drugs
- 5.2.2. Regulatory Impositions
- 5.2.3. Increasing Spending on Research and Development
- 5.2.4. Increasing Pipeline of Therapeutic Drugs
- 5.2.5. Rising Product Approvals
- 5.2.6.Growing Diabetes and Obesity Populations
- 5.2.7. Strategic Mergers and Acquisitions Among Local manufacturers
5.3. Market Dynamics
- 5.3.1. Drivers
- 5.3.2. Restraints
- 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

6.1. COVID-19 and Impact Analysis
- 6.1.1. By Drug Class
- 6.1.2. By Diabetes
- 6.1.3. By Route of Administration
- 6.1.4. By Distribution Channel
- 6.1.5. By Region
6.2. 2024 Market Scenario

7. Global Market Demand (in Value US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033

7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
- 7.2.1. Y-o-Y Growth Trend Analysis
- 7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Drug Class

8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Bn) Analysis, by Drug Class, 2019-2023
8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Drug Class, 2024-2033
- 8.3.1. Diuretics
- 8.3.2. Angiotensin Receptor Blockers
- 8.3.3. Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
- 8.3.4. Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
- 8.3.5. Others
8.4. Market Attractiveness Analysis, by Drug Class

9. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Diabetes

9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Bn) Analysis, By Diabetes, 2019-2023
9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Diabetes, 2024-2033
- 9.3.1. Type-1 Diabetes
- 9.3.2. Type-2 Diabetes
9.4. Market Attractiveness Analysis, by Diabetes

10. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Route of Administration

10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Bn) Analysis, By Diabetes, 2019-2023
10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Route of Administration, 2024-2033
- 10.3.1. Oral
- 10.3.2. Parenteral
- 10.3.3. Others
10.4. Market Attractiveness Analysis, by Route of Administration

11. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Distribution Channels

11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Bn) Analysis, By Diabetes, 2019-2023
11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Route of Administration, 2024-2033
- 11.3.1. Hospital Pharmacies
- 11.3.2. Retail Pharmacies
- 11.3.3. Online Pharmacies
- 11.3.4. Others
11.4. Market Attractiveness Analysis, by Route of Administration

12. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Region

12.1. Introduction
12.2. Historical Market Size (US$ Bn) Analysis, by Region, 2019-2023
12.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, By Region, 2024-2033
- 12.3.1. North America
- 12.3.2. Latin America
- 12.3.3. Europe
- 12.3.4. East Asia
- 12.3.5. South Asia
- 12.3.6. Oceania
- 12.3.7. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis, by Region

13. North America Market Analysis 2019-2023 and Forecast 2024-2033

13.1. Introduction
13.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
13.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
- 13.3.1. By Country
  - 13.3.1.1. U.S.
  - 13.3.1.2. Canada
- 13.3.2. By Drug Class
- 13.3.3. By Diabetes
- 13.3.4. By Route of Administration
- 13.3.5. By Distribution Channels
13.4. Market Attractiveness Analysis
- 13.4.1. By Country
- 13.4.2. By Drug Class
- 13.4.3. By Diabetes
- 13.4.4. By Route of Administration
- 13.4.5. By Distribution Channels
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
- 13.8.1. U.S. Market Analysis
  - 13.8.1.1. Introduction
  - 13.8.1.2. Market Analysis and Forecast, by Market Taxonomy
    - 13.8.1.2.1. By Drug Class
    - 13.8.1.2.2. By Diabetes
    - 13.8.1.2.3. By Route of Administration
    - 13.8.1.2.4. By Distribution Channels
- 13.8.2. Canada Market Analysis
  - 13.8.2.1. Introduction
  - 13.8.2.2. Market Analysis and Forecast, by Market Taxonomy
    - 13.8.2.2.1. By Drug Class
    - 13.8.2.2.2. By Diabetes
    - 13.8.2.2.3. By Route of Administration
    - 13.8.2.2.4. By Distribution Channels

14. Latin America Market Analysis 2019-2023 and Forecast 2024-2033

14.1. Introduction
14.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
14.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
- 14.3.1. By Country
  - 14.3.1.1. Mexico
  - 14.3.1.2. Brazil
  - 14.3.1.3. Argentina
  - 14.3.1.4. Rest of Latin America
- 14.3.2. By Drug Class
- 14.3.3. By Diabetes
- 14.3.4. By Route of Administration
- 14.3.5. By Distribution Channels
14.4. Market Attractiveness Analysis
- 14.4.1. By Country
- 14.4.2. By Drug Class
- 14.4.3. By Diabetes
- 14.4.4. By Route of Administration
- 14.4.5. By Distribution Channels
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
- 14.8.1. Mexico Market Analysis
  - 14.8.1.1. Introduction
  - 14.8.1.2. Market Analysis and Forecast, by Market Taxonomy
    - 14.8.1.2.1. By Drug Class
    - 14.8.1.2.2. By Diabetes
    - 14.8.1.2.3. By Route of Administration
    - 14.8.1.2.4. By Distribution Channels
- 14.8.2. Brazil Market Analysis
  - 14.8.2.1. Introduction
  - 14.8.2.2. Market Analysis and Forecast, by Market Taxonomy
    - 14.8.2.2.1. By Drug Class
    - 14.8.2.2.2. By Diabetes
    - 14.8.2.2.3. By Route of Administration
    - 14.8.2.2.4. By Distribution Channels
- 14.8.3. Argentina Market Analysis
  - 14.8.3.1. Introduction
  - 14.8.3.2. Market Analysis and Forecast, by Market Taxonomy
    - 14.8.3.2.1. By Drug Class
    - 14.8.3.2.2. By Diabetes
    - 14.8.3.2.3. By Route of Administration
    - 14.8.3.2.4. By Distribution Channels

15. Europe Market Analysis 2019-2023 and Forecast 2024-2033

15.1. Introduction
15.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
15.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
- 15.3.1. By Country
  - 15.3.1.1. Germany
  - 15.3.1.2. Italy
  - 15.3.1.3. France
  - 15.3.1.4. U.K.
  - 15.3.1.5. Spain
  - 15.3.1.6. BENELUX
  - 15.3.1.7. Russia
  - 15.3.1.8. Nordic Countries
  - 15.3.1.9. Rest of Europe
- 15.3.2. By Drug Class
- 15.3.3. By Diabetes
- 15.3.4. By Route of Administration
- 15.3.5. By Distribution Channels
15.4. Market Attractiveness Analysis
- 15.4.1. By Country
- 15.4.2. By Drug Class
- 15.4.3. By Diabetes
- 15.4.4. By Route of Administration
- 15.4.5. By Distribution Channels
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
- 15.8.1. Germany Market Analysis
  - 15.8.1.1. Introduction
  - 15.8.1.2. Market Analysis and Forecast, by Market Taxonomy
    - 15.8.1.2.1. By Drug Class
    - 15.8.1.2.2. By Diabetes
    - 15.8.1.2.3. By Route of Administration
    - 15.8.1.2.4. By Distribution Channels
- 15.8.2. Italy Market Analysis
  - 15.8.2.1. Introduction
  - 15.8.2.2. Market Analysis and Forecast, by Market Taxonomy
    - 15.8.2.2.1. By Drug Class
    - 15.8.2.2.2. By Diabetes
    - 15.8.2.2.3. By Route of Administration
    - 15.8.2.2.4. By Distribution Channels
- 15.8.3. France Market Analysis
  - 15.8.3.1. Introduction
  - 15.8.3.2. Market Analysis and Forecast, by Market Taxonomy
    - 15.8.3.2.1. By Drug Class
    - 15.8.3.2.2. By Diabetes
    - 15.8.3.2.3. By Route of Administration
    - 15.8.3.2.4. By Distribution Channels
- 15.8.4. U.K. Market Analysis
  - 15.8.4.1. Introduction
  - 15.8.4.2. Market Analysis and Forecast, by Market Taxonomy
    - 15.8.4.2.1. By Drug Class
    - 15.8.4.2.2. By Diabetes
    - 15.8.4.2.3. By Route of Administration
    - 15.8.4.2.4. By Distribution Channels
- 15.8.5. Spain Market Analysis
  - 15.8.5.1. Introduction
  - 15.8.5.2. Market Analysis and Forecast, by Market Taxonomy
    - 15.8.5.2.1. By Drug Class
    - 15.8.5.2.2. By Diabetes
    - 15.8.5.2.3. By Route of Administration
    - 15.8.5.2.4. By Distribution Channels
- 15.8.6. BENELUX Market Analysis
  - 15.8.6.1. Introduction
  - 15.8.6.2. Market Analysis and Forecast, by Market Taxonomy
    - 15.8.6.2.1. By Drug Class
    - 15.8.6.2.2. By Diabetes
    - 15.8.6.2.3. By Route of Administration
    - 15.8.6.2.4. By Distribution Channels
- 15.8.7. Russia Market Analysis
  - 15.8.7.1. Introduction
  - 15.8.7.2. Market Analysis and Forecast, by Market Taxonomy
    - 15.8.7.2.1. By Drug Class
    - 15.8.7.2.2. By Diabetes
    - 15.8.7.2.3. By Route of Administration
    - 15.8.7.2.4. By Distribution Channels
- 15.8.8. Nordic Countries Market Analysis
  - 15.8.8.1. Introduction
  - 15.8.8.2. Market Analysis and Forecast, by Market Taxonomy
    - 15.8.8.2.1. By Drug Class
    - 15.8.8.2.2. By Diabetes
    - 15.8.8.2.3. By Route of Administration
    - 15.8.8.2.4. By Distribution Channels

16. East Asia Market Analysis 2019-2023 and Forecast 2024-2033

16.1. Introduction
16.2. Historical Market End User (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
16.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
- 16.3.1. By Country
  - 16.3.1.1. China
  - 16.3.1.2. Japan
  - 16.3.1.3. South Korea
- 16.3.2. By Drug Class
- 16.3.3. By Diabetes
- 16.3.4. By Route of Administration
- 16.3.5. By Distribution Channels
16.4. Market Attractiveness Analysis
- 16.4.1. By Drug Class
- 16.4.2. By Diabetes
- 16.4.3. By Route of Administration
- 16.4.4. By Distribution Channels
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
- 16.8.1. China Market Analysis
  - 16.8.1.1. Introduction
  - 16.8.1.2. Market Analysis and Forecast, by Market Taxonomy
    - 16.8.1.2.1. By Drug Class
    - 16.8.1.2.2. By Diabetes
    - 16.8.1.2.3. By Route of Administration
    - 16.8.1.2.4. By Distribution Channels
- 16.8.2. Japan Market Analysis
  - 16.8.2.1. Introduction
  - 16.8.2.2. Market Analysis and Forecast, by Market Taxonomy
    - 16.8.2.2.1. By Drug Class
    - 16.8.2.2.2. By Diabetes
    - 16.8.2.2.3. By Route of Administration
    - 16.8.2.2.4. By Distribution Channels
- 16.8.3. South Korea Market Analysis
  - 16.8.3.1. Introduction
  - 16.8.3.2. Market Analysis and Forecast, by Market Taxonomy
    - 16.8.3.2.1. By Drug Class
    - 16.8.3.2.2. By Diabetes
    - 16.8.3.2.3. By Route of Administration
    - 16.8.3.2.4. By Distribution Channels

17. South Asia Market Analysis 2019-2023 and Forecast 2024-2033

17.1. Introduction
17.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
17.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
- 17.3.1. By Country
  - 17.3.1.1. India
  - 17.3.1.2. Indonesia
  - 17.3.1.3. Malaysia
  - 17.3.1.4. Thailand
  - 17.3.1.5. Rest of South Asia
- 17.3.2. By Drug Class
- 17.3.3. By Diabetes
- 17.3.4. By Route of Administration
- 17.3.5. By Distribution Channels
17.4. Market Attractiveness Analysis
- 17.4.1. By Country
- 17.4.2. By Drug Class
- 17.4.3. By Diabetes
- 17.4.4. By Route of Administration
- 17.4.5. By Distribution Channels
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
- 17.8.1. India Market Analysis
  - 17.8.1.1. Introduction
  - 17.8.1.2. Market Analysis and Forecast, by Market Taxonomy
    - 17.8.1.2.1. By Drug Class
    - 17.8.1.2.2. By Diabetes
    - 17.8.1.2.3. By Route of Administration
    - 17.8.1.2.4. By Distribution Channels
- 17.8.2. Indonesia Market Analysis
  - 17.8.2.1. Introduction
  - 17.8.2.2. Market Analysis and Forecast, by Market Taxonomy
    - 17.8.2.2.1. By Drug Class
    - 17.8.2.2.2. By Diabetes
    - 17.8.2.2.3. By Route of Administration
    - 17.8.2.2.4. By Distribution Channels
- 17.8.3. Malaysia Market Analysis
  - 17.8.3.1. Introduction
  - 17.8.3.2. Market Analysis and Forecast, by Market Taxonomy
    - 17.8.3.2.1. By Drug Class
    - 17.8.3.2.2. By Diabetes
    - 17.8.3.2.3. By Route of Administration
    - 17.8.3.2.4. By Distribution Channels
- 17.8.4. Thailand Market Analysis
  - 17.8.4.1. Introduction
  - 17.8.4.2. Market Analysis and Forecast, by Market Taxonomy
    - 17.8.4.2.1. By Drug Class
    - 17.8.4.2.2. By Diabetes
    - 17.8.4.2.3. By Route of Administration
    - 17.8.4.2.4. By Distribution Channels

18. Oceania Market 2019-2023 and Forecast 2024-2033

18.1. Introduction
18.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
18.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
- 18.3.1. By Country
  - 18.3.1.1. Australia
  - 18.3.1.2. New Zealand
- 18.3.2. By Drug Class
- 18.3.3. By Diabetes
- 18.3.4. By Route of Administration
- 18.3.5. By Distribution Channels
18.4. Market Attractiveness Analysis
- 18.4.1. By Country
- 18.4.2. By Drug Class
- 18.4.3. By Diabetes
- 18.4.4. By Route of Administration
- 18.4.5. By Distribution Channels
18.5. Key Market Participants - Intensity Mapping
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
- 18.8.1. Australia Market Analysis
  - 18.8.1.1. Introduction
  - 18.8.1.2. Market Analysis and Forecast, by Market Taxonomy
    - 18.8.1.2.1. By Drug Class
    - 18.8.1.2.2. By Diabetes
    - 18.8.1.2.3. By Route of Administration
    - 18.8.1.2.4. By Distribution Channels
- 18.8.2. New Zealand Market Analysis
  - 18.8.2.1. Introduction
  - 18.8.2.2. Market Analysis and Forecast, by Market Taxonomy
    - 18.8.2.2.1. By Drug Class
    - 18.8.2.2.2. By Diabetes
    - 18.8.2.2.3. By Route of Administration
    - 18.8.2.2.4. By Distribution Channels

19. Middle East and Africa (MEA) Market Analysis 2019-2023 and Forecast 2024-2033

19.1. Introduction
19.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
19.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
- 19.3.1. By Country
  - 19.3.1.1. GCC Countries
  - 19.3.1.2. Turkiye
  - 19.3.1.3. South Africa
  - 19.3.1.4. North Africa
  - 19.3.1.5. Rest of Middle East and Africa
- 19.3.2. By Drug Class
- 19.3.3. By Diabetes
- 19.3.4. By Route of Administration
- 19.3.5. By Distribution Channels
19.4. Market Attractiveness Analysis
- 19.4.1. By Drug Class
- 19.4.2. By Diabetes
- 19.4.3. By Route of Administration
- 19.4.4. By Distribution Channels
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
- 19.8.1. GCC Countries Market Analysis
  - 19.8.1.1. Introduction
  - 19.8.1.2. Market Analysis and Forecast, by Market Taxonomy
    - 19.8.1.2.1. By Drug Class
    - 19.8.1.2.2. By Diabetes
    - 19.8.1.2.3. By Route of Administration
    - 19.8.1.2.4. By Distribution Channels
- 19.8.2. Turkiye Market Analysis
  - 19.8.2.1. Introduction
  - 19.8.2.2. Market Analysis and Forecast, by Market Taxonomy
    - 19.8.2.2.1. By Drug Class
    - 19.8.2.2.2. By Diabetes
    - 19.8.2.2.3. By Route of Administration
    - 19.8.2.2.4. By Distribution Channels
- 19.8.3. South Africa Market Analysis
  - 19.8.3.1. Introduction
  - 19.8.3.2. Market Analysis and Forecast, by Market Taxonomy
    - 19.8.3.2.1. By Drug Class
    - 19.8.3.2.2. By Diabetes
    - 19.8.3.2.3. By Route of Administration
    - 19.8.3.2.4. By Distribution Channels
- 19.8.4. North Africa Market Analysis
  - 19.8.4.1. Introduction
  - 19.8.4.2. Market Analysis and Forecast, by Market Taxonomy
    - 19.8.4.2.1. By Drug Class
    - 19.8.4.2.2. By Diabetes
    - 19.8.4.2.3. By Route of Administration
    - 19.8.4.2.4. By Distribution Channels

20. Market Structure Analysis

20.1. Market Analysis, by Tier of Companies
20.2. Market Share Analysis of Top Players
20.3. Market Presence Analysis

21. Competition Analysis

21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
- 21.3.1. AstraZeneca (UK.)
  - 21.3.1.1. Overview
  - 21.3.1.2. Product Portfolio
  - 21.3.1.3. Sales Footprint
  - 21.3.1.4. Key Financials
  - 21.3.1.5. SWOT Analysis
  - 21.3.1.6. Strategy Overview
    - 21.3.1.6.1. Marketing Strategy
    - 21.3.1.6.2. Product Strategy
    - 21.3.1.6.3. Channel Strategy
- 21.3.2. Pfizer Inc (US.)
  - 21.3.2.1. Overview
  - 21.3.2.2. Product Portfolio
  - 21.3.2.3. Sales Footprint
  - 21.3.2.4. Key Financials
  - 21.3.2.5. SWOT Analysis
  - 21.3.2.6. Strategy Overview
    - 21.3.2.6.1. Marketing Strategy
    - 21.3.2.6.2. Product Strategy
    - 21.3.2.6.3. Channel Strategy
- 21.3.3. Allergan, Inc (Ireland)
  - 21.3.3.1. Overview
  - 21.3.3.2. Product Portfolio
  - 21.3.3.3. Sales Footprint
  - 21.3.3.4. Key Financials
  - 21.3.3.5. SWOT Analysis
  - 21.3.3.6. Strategy Overview
    - 21.3.3.6.1. Marketing Strategy
    - 21.3.3.6.2. Product Strategy
    - 21.3.3.6.3. Channel Strategy
- 21.3.4. Bristol-Myers Squibb Company (US.)
  - 21.3.4.1. Overview
  - 21.3.4.2. Product Portfolio
  - 21.3.4.3. Sales Footprint
  - 21.3.4.4. Key Financials
  - 21.3.4.5. SWOT Analysis
  - 21.3.4.6. Strategy Overview
    - 21.3.4.6.1. Marketing Strategy
    - 21.3.4.6.2. Product Strategy
    - 21.3.4.6.3. Channel Strategy
- 21.3.5. Endo International plc (Ireland)
  - 21.3.5.1. Overview
  - 21.3.5.2. Product Portfolio
  - 21.3.5.3. Sales Footprint
  - 21.3.5.4. Key Financials
  - 21.3.5.5. SWOT Analysis
  - 21.3.5.6. Strategy Overview
    - 21.3.5.6.1. Marketing Strategy
    - 21.3.5.6.2. Product Strategy
    - 21.3.5.6.3. Channel Strategy
- 21.3.6. Dr. Reddy's Laboratories Ltd (India)
  - 21.3.6.1. Overview
  - 21.3.6.2. Product Portfolio
  - 21.3.6.3. Sales Footprint
  - 21.3.6.4. Key Financials
  - 21.3.6.5. SWOT Analysis
  - 21.3.6.6. Strategy Overview
    - 21.3.6.6.1. Marketing Strategy
    - 21.3.6.6.2. Product Strategy
    - 21.3.6.6.3. Channel Strategy
- 21.3.7. Sun Pharmaceutical Industries Ltd (India)
  - 21.3.7.1. Overview
  - 21.3.7.2. Product Portfolio
  - 21.3.7.3. Sales Footprint
  - 21.3.7.4. Key Financials
  - 21.3.7.5. SWOT Analysis
  - 21.3.7.6. Strategy Overview
    - 21.3.7.6.1. Marketing Strategy
    - 21.3.7.6.2. Product Strategy
    - 21.3.7.6.3. Channel Strategy
- 21.3.8. Teva Pharmaceutical Industries Ltd (Israel)
  - 21.3.8.1. Overview
  - 21.3.8.2. Product Portfolio
  - 21.3.8.3. Sales Footprint
  - 21.3.8.4. Key Financials
  - 21.3.8.5. SWOT Analysis
  - 21.3.8.6. Strategy Overview
    - 21.3.8.6.1. Marketing Strategy
    - 21.3.8.6.2. Product Strategy
    - 21.3.8.6.3. Channel Strategy
- 21.3.9. Novartis AG (Switzerland)
  - 21.3.9.1. Overview
  - 21.3.9.2. Product Portfolio
  - 21.3.9.3. Sales Footprint
  - 21.3.9.4. Key Financials
  - 21.3.9.5. SWOT Analysis
  - 21.3.9.6. Strategy Overview
    - 21.3.9.6.1. Marketing Strategy
    - 21.3.9.6.2. Product Strategy
    - 21.3.9.6.3. Channel Strategy
- 21.3.10. Eli Lilly and Company (India)
  - 21.3.10.1. Overview
  - 21.3.10.2. Product Portfolio
  - 21.3.10.3. Sales Footprint
  - 21.3.10.4. Key Financials
  - 21.3.10.5. SWOT Analysis
  - 21.3.10.6. Strategy Overview
    - 21.3.10.6.1. Marketing Strategy
    - 21.3.10.6.2. Product Strategy
    - 21.3.10.6.3. Channel Strategy
- 21.3.11. Mylan NV (US.)
  - 21.3.11.1. Overview
  - 21.3.11.2. Product Portfolio
  - 21.3.11.3. Sales Footprint
  - 21.3.11.4. Key Financials
  - 21.3.11.5. SWOT Analysis
  - 21.3.11.6. Strategy Overview
    - 21.3.11.6.1. Marketing Strategy
    - 21.3.11.6.2. Product Strategy
    - 21.3.11.6.3. Channel Strategy
- 21.3.12. Cipla Inc (India)
  - 21.3.12.1. Overview
  - 21.3.12.2. Product Portfolio
  - 21.3.12.3. Sales Footprint
  - 21.3.12.4. Key Financials
  - 21.3.12.5. SWOT Analysis
  - 21.3.12.6. Strategy Overview
    - 21.3.12.6.1. Marketing Strategy
    - 21.3.12.6.2. Product Strategy
    - 21.3.12.6.3. Channel Strategy
- 21.3.13. Lupin (India)
  - 21.3.13.1. Overview
  - 21.3.13.2. Product Portfolio
  - 21.3.13.3. Sales Footprint
  - 21.3.13.4. Key Financials
  - 21.3.13.5. SWOT Analysis
  - 21.3.13.6. Strategy Overview
    - 21.3.13.6.1. Marketing Strategy
    - 21.3.13.6.2. Product Strategy
    - 21.3.13.6.3. Channel Strategy
- 21.3.14. Aurobindo Pharma (India)
  - 21.3.14.1. Overview
  - 21.3.14.2. Product Portfolio
  - 21.3.14.3. Sales Footprint
  - 21.3.14.4. Key Financials
  - 21.3.14.5. SWOT Analysis
  - 21.3.14.6. Strategy Overview
    - 21.3.14.6.1. Marketing Strategy
    - 21.3.14.6.2. Product Strategy
    - 21.3.14.6.3. Channel Strategy
- 21.3.15. Sanofi (France)
  - 21.3.15.1. Overview
  - 21.3.15.2. Product Portfolio
  - 21.3.15.3. Sales Footprint
  - 21.3.15.4. Key Financials
  - 21.3.15.5. SWOT Analysis
  - 21.3.15.6. Strategy Overview
    - 21.3.15.6.1. Marketing Strategy
    - 21.3.15.6.2. Product Strategy
    - 21.3.15.6.3. Channel Strategy
- 21.3.16. Fresenius SE & Co. KGaA (Germany)
  - 21.3.16.1. Overview
  - 21.3.16.2. Product Portfolio
  - 21.3.16.3. Sales Footprint
  - 21.3.16.4. Key Financials
  - 21.3.16.5. SWOT Analysis
  - 21.3.16.6. Strategy Overview
    - 21.3.16.6.1. Marketing Strategy
    - 21.3.16.6.2. Product Strategy
    - 21.3.16.6.3. Channel Strategy
- 21.3.17. F. Hoffmann-La Roche Ltd (Switzerland)
  - 21.3.17.1. Overview
  - 21.3.17.2. Product Portfolio
  - 21.3.17.3. Sales Footprint
  - 21.3.17.4. Key Financials
  - 21.3.17.5. SWOT Analysis
  - 21.3.17.6. Strategy Overview
    - 21.3.17.6.1. Marketing Strategy
    - 21.3.17.6.2. Product Strategy
    - 21.3.17.6.3. Channel Strategy
- 21.3.18. Takeda Pharmaceutical Company Limited (Japan)
  - 21.3.18.1. Overview
  - 21.3.18.2. Product Portfolio
  - 21.3.18.3. Sales Footprint
  - 21.3.18.4. Key Financials
  - 21.3.18.5. SWOT Analysis
  - 21.3.18.6. Strategy Overview
    - 21.3.18.6.1. Marketing Strategy
    - 21.3.18.6.2. Product Strategy
    - 21.3.18.6.3. Channel Strategy
- 21.3.19. Abbott (US.)
  - 21.3.19.1. Overview
  - 21.3.19.2. Product Portfolio
  - 21.3.19.3. Sales Footprint
  - 21.3.19.4. Key Financials
  - 21.3.19.5. SWOT Analysis
  - 21.3.19.6. Strategy Overview
    - 21.3.19.6.1. Marketing Strategy
    - 21.3.19.6.2. Product Strategy
    - 21.3.19.6.3. Channel Strategy